Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
MT 63-78
Cat. No.:
0225LY-0587
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
MT 63-78 is a direct AMPK activator (EC50: 25 μM) that provides antitumor effects by blocking mTORC1 and lipogenesis, leading to apoptosis and mitotic arrest in prostate cancer.
Synonym:
1179347-65-9; 5-{2',6'-Dihydroxy-[1,1'-biphenyl]-4-yl}-1H-indole-3-carbonitrile; 5-[4-(2,6-dihydroxyphenyl)phenyl]-1H-indole-3-carbonitrile
CAS No.:
1179347-65-9
Compound CID:
59145386
Formula:
C21H14N2O2
Formula Weight:
326.35
Specification
Targets&IC50:
AMPK: 25 μM (EC50); mTORC1:
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MT 63-78 can be used in metabolism research to evaluate its potency as a direct activator of the AMPK complex.
Library Information
Target:
AMPK; mTOR
Receptor:
AMPK; mTORC1
Pathways:
Chromatin/Epigenetic; Apoptosis; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-8
Plate Location:
f2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
3.27 mg/mL; 10.02 mM
